Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
137
resultados
Última actualización
31/08/2024 [07:29:00]
Resumen de: CN116064763A
The invention relates to the field of disease diagnosis and treatment, in particular to disease diagnosis and treatment with IFP35 and NMI as targets. The invention discloses application of interferon-induced protein 35kD and/or detection of N-Myc interaction protein in diagnosis or prognosis evaluation of inflammatory bowel diseases, arthritis, psoriasis, systemic lupus erythematosus, nervous system diseases, lung injury and peritonitis, in evaluation of the severity of arthritis and in distinguishing of tumor diseases and thoracic infection diseases for the first time. The ROC curve chart shows that the interferon-induced protein 35kD and/or the N-Myc interaction detection protein can be used as a marker for diagnosis or prognosis evaluation of inflammatory bowel diseases, arthritis, psoriasis, systemic lupus erythematosus, nervous system diseases, lung injury and peritonitis, evaluation of the severity of arthritis and distinguishing of tumor diseases and thoracic infection diseases.
Resumen de: WO2024178157A1
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: US2024285231A1
Disclosed herein, in some aspects, are systems and methods for determining and/or monitoring a stool condition for a subject. In some embodiments, the stool condition is based on one or more images of stool of a subject. In some embodiments, the stool condition correlates with a stool assessment comprising i) a characterization of the stool according to a plurality of characteristics, and/or ii) identifying one or more medical conditions, illnesses, and/or diseases associated with the stool. In some embodiments, the stool condition is determined using one or more Artificial Intelligence engines using a trained data set. In some embodiments, the stool condition is based on one or more stool assessments performed for one or more stools corresponding to one or more bowel movements over a period of time.
Resumen de: WO2024177256A1
The present invention relates to a companion diagnostic biomarker composition for predicting anti-TNF treatment responsiveness to Crohn's disease. The present invention can be effectively used as a companion diagnostic biomarker composition for predicting anti-TNF treatment responsiveness to Crohn's disease by confirming that the expression of specific genes (SLAMF7, CXCL6, CXCL1, MLKL, BMP6, and LAX1) is increased in a patient group having low or no anti-TNF treatment responsiveness to Crohn's disease.
Resumen de: AU2024205664A1
EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
Resumen de: US2024199700A1
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Resumen de: EP4417707A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: GB2627344A
Cannabinoid for use in prevention or treatment of a symptom of an autism spectrum disorder by preventing or reducing gastrointestinal inflammation, gastrointestinal hyperpermeability and/or colonic muscle thinning. The cannabinoid is administered to a subject who has or suspected of having gastrointestinal hyperpermeability, gastrointestinal inflammation, and/or colonic thinning. The symptom of autism may be a behavioural symptom and/or a gastrointestinal symptom. The subject may have been diagnosed with Crohn’s disease, coeliac disease, ulcerative colitis, type I diabetes, arthritis including spondylarthritis and psoriatic arthritis, or inflammation, particularly gastrointestinal inflammation. Also disclosed is a cannabinoid for use in the prevention, treatment, or reduction of gastrointestinal hyperpermeability or gastrointestinal inflammation. The cannabinoid may be cannabidiol (CBD), tetrahydrocannabinol (THC) or a combination thereof. The cannabinoid may be suitable for oral administration, e.g. in the form of a pharmaceutical or nutritional composition. The subject may be human and may be a child. Also disclosed is a dosage form of the cannabinoid comprising 0.1-20 mg/kg body weight of CBD and/or 0.05-6 mg/kg body weight of THC.
Resumen de: WO2024159559A1
A protein marker combination for prediction, diagnosis or prognosis of colorectal cancer, and a use and system based on the protein marker combination. The protein marker combination comprises at least one selected from LRG1, SERPINA1, ITIH3, CP, ORM1, C9, IGFBP2, and CNDP1. The protein marker combination provides a blood plasma-based non-invasive screening method for the prediction of early colorectal cancer and even advanced precancerous lesions. By using the method and system to perform the prediction, diagnosis or prognosis of colorectal cancer, the advantage of being non-invasive to a patient is achieved, materials are accessible, less blood plasma samples are used, and high sensitivity and specificity are achieved.
Resumen de: WO2024159559A1
A protein marker combination for prediction, diagnosis or prognosis of colorectal cancer, and a use and system based on the protein marker combination. The protein marker combination comprises at least one selected from LRG1, SERPINA1, ITIH3, CP, ORM1, C9, IGFBP2, and CNDP1. The protein marker combination provides a blood plasma-based non-invasive screening method for the prediction of early colorectal cancer and even advanced precancerous lesions. By using the method and system to perform the prediction, diagnosis or prognosis of colorectal cancer, the advantage of being non-invasive to a patient is achieved, materials are accessible, less blood plasma samples are used, and high sensitivity and specificity are achieved.
Resumen de: US2024272175A1
Provided herein are methods for diagnosing functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome, comprising detecting IgG antibodies in a sample obtained from a subject, wherein the IgG antibodies recognise one or more antigens from Streptococcus salivarius. Also provided are kits for detecting IgG antibodies for use in the diagnosis of functional gastrointestinal disorders, and methods for selecting subjects for treatment for functional gastrointestinal disorders.
Resumen de: EP4285988A2
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Resumen de: WO2024160832A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: WO2024159559A1
A protein marker combination for prediction, diagnosis or prognosis of colorectal cancer, and a use and system based on the protein marker combination. The protein marker combination comprises at least one selected from LRG1, SERPINA1, ITIH3, CP, ORM1, C9, IGFBP2, and CNDP1. The protein marker combination provides a blood plasma-based non-invasive screening method for the prediction of early colorectal cancer and even advanced precancerous lesions. By using the method and system to perform the prediction, diagnosis or prognosis of colorectal cancer, the advantage of being non-invasive to a patient is achieved, materials are accessible, less blood plasma samples are used, and high sensitivity and specificity are achieved.
Resumen de: WO2024163419A2
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: WO2023056417A1
The present disclosure is generally relates to methods of treating ulcerative colitis. The methods are particularly suitable for treating bowel urgency a specific sub-group of patients with ulcerative colitis and having bowel urgency.
Resumen de: US2022162703A1
The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNASET2, TL1A and/or IFN-γ. The invention further provides a process for patient identification and/or stratification.
Resumen de: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: US2022372544A1
Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: US2024254449A1
Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
Resumen de: US2024254217A1
The present disclosure generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.
Resumen de: US2024252587A1
The present invention provides methods and taste-modifying kits for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods and taste-modifying kits can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.
Resumen de: US2024252556A1
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
Resumen de: WO2024152380A1
Panels of metabolites for use as diagnostic biomarkers for detecting IBD in a subject and panels of metabolites for use as diagnostic biomarkers are provided for discriminating between UC and CD, which are the main subtypes of IBD. Panels of metabolites for used as diagnostic biomarkers for discriminating between IBD and colorectal polyp are also provided. These diagnostic biomarkers are serum metabolites associated with gut microbiome. Systems(100) and methods for detecting IBD and for discriminating between UC and CD using the panels of metabolites are also provided.
Nº publicación: US2024247315A1 25/07/2024
Solicitante:
YEDA RES AND DEVELOPMENT CO LTD [IL]
SHEBA IMPACT LTD [IL]
YEDA RESEARCH AND DEVELOPMENT CO. LTD,
SHEBA IMPACT LTD
Resumen de: US2024247315A1
A method of diagnosing an inflammatory bowel disease (IBD) of a subject is disclosed. The method comprises analyzing the RNA expression level of particular human gene in a fecal RNA sample of the subject, wherein when the expression level is above a predetermined amount it is indicative of the inflammatory bowel disease.
BOPI
Sede Electrónica
